Icatibant Piramal (Icatibant)

Icatibant works as a selective competitive antagonist of the bradykinin B2 receptor. It prevents bradykinin from binding to this receptor, thereby inhibiting the vasodilation and increased vascular permeability that cause the swelling seen in hereditary angioedema.

The dose of icatibant is determined by the prescribing clinician based on the patient’s condition and regulatory guidance. The prescriber decides the exact amount, timing, and number of injections required for each acute HAE attack.

Safety data for icatibant in pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and any necessary import documentation.

The primary alternative for HAE attacks is C1‑inhibitor concentrate, which replaces the deficient protein. Icatibant directly blocks bradykinin receptors, offering a rapid, subcutaneous option that does not require plasma‑derived products. Choice depends on patient preference, attack severity, and clinical guidelines.

Icatibant should be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. If temporary temperature excursions occur, follow the manufacturer’s stability guidance before use.

Icatibant is given by subcutaneous injection, typically into the abdomen or thigh. The injection site should be cleaned with an alcohol swab, and the solution administered using the supplied pre‑filled syringe or autoinjector according to the prescriber’s instructions.

The most serious risks include severe hypersensitivity reactions such as anaphylaxis, laryngeal edema that can compromise the airway, and significant hypotension. Patients should be monitored closely after injection, and any signs of these reactions require immediate medical attention.

Icatibant should not be used in individuals with known hypersensitivity to icatibant or any of its excipients. Caution is also advised for patients with severe renal or hepatic impairment, and those taking ACE inhibitors or ARBs without appropriate monitoring.